PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 30, 2026Pharmacoepidemiology0 citationsOpen Access

Characterization of the Enrollment of Pregnant and Breastfeeding People in Cardiovascular Randomized Clinical Trials

View Full Paper
TMTianhui MaSMSimona MiljanicHTHasti Tajdari

Key Result

Among 586 cardiovascular RCTs published between 2019 and 2023, only 0.7% permitted the inclusion of pregnant people, and none explicitly permitted breastfeeding people.

Study Design

Type

Systematic Review (n=586)

Structured PICO

P
Population
586 cardiovascular randomized clinical trials published between 2019 and 2023 were analyzed to assess the inclusion and exclusion of pregnant and breastfeeding people.
O
Outcome
Representation of pregnant and breastfeeding people in cardiovascular RCTs and whether inclusion increased following the 2018 FDA policy change.

Pregnant and breastfeeding people are systematically excluded from cardiovascular RCTs, and the justification for their exclusion is rarely provided, despite the 2018 FDA policy change.

Abstract

Background/Objectives: Pregnant and breastfeeding people require special considerations for enrollment in clinical trials. However, the baseline proportion of cardiovascular clinical trials including pregnant and breastfeeding people remains unclear. The objective of this study was to characterize the representation of pregnant and breastfeeding people in cardiovascular randomized clinical trials (RCTs) and to determine whether inclusion has increased following the 2018 removal of pregnancy from the FDA’s “vulnerable population” designation. Methods: We screened eight high-impact general medicine and specialty journals for cardiovascular RCTs published between 1 January 2019 and 31 December 2023. We included RCTs examining pharmacological, behavioral, educational, device, or procedural interventions. We excluded RCTs that recruited exclusively male, pediatric, geriatric, or postmenopausal populations, and those specifically designed for obstetrical populations. We also excluded publications reporting follow-up or subgroup, pooled, or secondary analyses of previously published trials. Data from RCTs were independently extracted in duplicate following the PRISMA guidelines. We examined each RCT for pregnancy and breastfeeding inclusion criteria, rationale for exclusion, and contraception requirements. Results: Of 3764 citations identified, 586 met the inclusion criteria. In total, four (0.7%) RCTs permitted inclusion of pregnant people, 382 (65%) explicitly stated their exclusion, and 200 (34%) did not provide specific enrolment criteria for them. The few studies that explicitly stated exclusion of pregnant people (31/382, 8.1%) provided a rationale. 225 (38%) RCTs explicitly stated exclusion of breastfeeding people, and none explicitly permitted inclusion. There was no significant difference in the proportion of pregnant or breastfeeding people included or excluded from RCTs that began enrollment before 2018 versus after 2018. Conclusions: Pregnant and breastfeeding people are primarily excluded from cardiovascular RCTs, and the justification for their exclusion is rarely provided.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ma et al. (2026) conducted a systematic review in Cardiovascular disease (n=586). Cardiovascular RCTs was evaluated on Proportion of RCTs permitting inclusion of pregnant people. Among 586 cardiovascular RCTs published between 2019 and 2023, only 0.7% permitted the inclusion of pregnant people, and none explicitly permitted breastfeeding people.

synapsesocial.com/papers/6a1f507ad09bc027e4834f44https://doi.org/10.3390/pharma5020016
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effectiveness of the Family Heart Talk Communication Tool in Improving Family Member Screening for Dilated Cardiomyopathy: Results of a Randomized Trial2023 · 12 citations
  2. 2OUTSMART HF2020 · 31 citations
  3. 3Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR2021 · 265 citations
  4. 4Cardiovascular disease in pregnancy: Prevalence and obstetric outcomes in a Swedish population‐based cohort study between 2000 and 20192024 · 2 citations
  5. 5Eligibility Criteria of Randomized Controlled Trials Published in High-Impact General Medical Journals2007 · 1,070 citations